Wish to keep on high of the science and politics driving biotech right now? Enroll to get our biotech publication in your inbox.
Completely happy Tuesday! Adam Feuerstein, right here, filling in on your common Readout correspondents.
Biotech determined to launch all of the remaining information for the yr simply earlier than Thanksgiving. It’s a bit loopy on the market this morning.
Talking of Turkey Day, within the Nineteen Seventies, my paternal grandparents lived on Central Park West in NYC. That they had a view of the parade route from their residence balcony. One in all my most cherished childhood reminiscences.
The necessity-to-know this morning
- Roche stated it might purchase Poseida Therapeutics, which is designing off-the-shelf CAR-T therapies for each most cancers and autoimmune ailments, for roughly $1 billion upfront.
- Sarepta Therapeutics and Arrowhead Prescribed drugs signed a partnership settlement that may grant Sarepta world licensing rights to seven drug packages from Arrowhead centered on genetic ailments affecting muscle tissues and nerves. Sarepta is paying Arrowhead $500 million in money and making a $325 million fairness funding.
Amgen’s MariTide information are right here!
New information from a carefully tracked, mid-stage research of the Amgen weight problems drug, referred to as MariTide, confirmed that it helped contributors lose a considerable quantity of weight, however questions on how aggressive it might be look like shaping the response to the information, with the corporate’s share value falling on the announcement.
MariTide led to a median of roughly 20% weight reduction over a yr within the Section 2 research in contributors who had weight problems or who have been obese with out sort 2 diabetes. The corporate added that weight reduction had not plateaued at that time, suggesting that there was potential for extra weight reduction.
Amongst contributors who did have sort 2 diabetes, who usually lose much less weight on this class of medication, MariTide led to a median of roughly 17% weight reduction after a yr.
Roche’s TIGIT troubles proceed
The Swiss pharma big stated this morning that an experimental most cancers therapy failed to enhance survival in a significant lung most cancers research, a outcome that may additional stoke doubts about the drug’s goal.
In a brief assertion, Roche stated {that a} mixture of the drug, referred to as tiragolumab, with its present medication Tecentriq didn’t outperform Tecentriq alone on the research’s main endpoint of total survival. The Section 3 research, often called SKYSCRAPER-01, included greater than 500 sufferers with a type of superior non-small cell lung most cancers.
Tiragolumab was designed to focus on a protein referred to as TIGIT, which lately was seen as the subsequent blockbuster alternative in most cancers immunotherapy. However early medical information have been combined, elevating questions on whether or not corporations had cracked tips on how to efficiently goal TIGIT.
Cassava and its Alzheimer’s drug are carried out
I spent 4 loopy years writing about Cassava Sciences. Yesterday, the story ended precisely as I and lots of others knew it might — with the corporate’s experimental drug for Alzheimer’s illness, simufilam, proving to be nothing greater than a placebo in a big medical trial.
The unfavorable final result is devastating for the practically 2,000 contributors on this research and a second research additionally shut down yesterday. Medical trials in Alzheimer’s fail all too continuously, however simufilam was constructed on falsified analysis and deceptive efficacy claims. The drug ought to by no means have superior this far.
Buyers misplaced, too. Yesterday, alone, Cassava’s inventory value fell 83%, shedding greater than $1 billion in market worth. Sadly, many of those individuals, practically all retail buyers, purchased into the looney, meme-stock conspiracy theories that saved Cassava afloat.
A novel Alzheimer’s goal misses the mark
Alector Therapeutics stated that its Section 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what had been one of many main darkish horse approaches to treating the neurodegenerative illness.
The drug, referred to as AL002, is designed to activate a gaggle of surveilling neuronal immune cells referred to as microglia. It was amongst a number of efforts, now in or nearing medical trials, predicated on the notion that modulating the mind’s immune system might sluggish the degenerative illness.
Within the 381-person trial, nonetheless, sufferers who acquired AL002 didn’t decline extra slowly than sufferers who have been on placebo, as measured by a scale referred to as the Medical Dementia Score Sum of Packing containers.
Inside the marketplace for GLP-1 copycats
Within the newest STAT deep dive video, my colleague Alex Hogan explains the loophole that enables sure pharmacies to make generic variations of the blockbuster GLP-1 medication for weight reduction, Ozempic and Wegovy.
Extra reads
- Medicare strikes to broaden protection for weight-loss medication Wegovy, Zepbound, STAT
- Minnesota turns into first state to launch report on 340B drug low cost program for ‘safety-net’ hospitals, STAT
- Trump group requested Warp Velocity chief to go NIH, might search extra conventional decide for function, Endpoints